Matches in SemOpenAlex for { <https://semopenalex.org/work/W2377771057> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- W2377771057 endingPage "309" @default.
- W2377771057 startingPage "306" @default.
- W2377771057 abstract "Objective To evaluate the efficacy and safety of mizolastine versus loratadine in the treatment of chronic idiopathic urticaria(CIU).Methods A five-centre,double-blind,randomized,comparative study was conducted.The patients were randomly divided into two therapeutic groups:received mizolastine(10mg)or loratadine(10mg)once daily for28days.Itching,number of wheals,diameter of the largest wheal and lasting time of urticarial attacks were evaluated.According to a scale from0(absent)to3(severe),the patient-rated severity of itch measured by visual analogue scale(VAS).The number of weekly urticaria episodes was recorded.Control visits were scheduled after7,14and28days of therapy.Results213patients were enrolled and206patients completed the trial,including104cases in mizolastine group and102cases in loratadine group.There were12patients withdrew and dropped out from the trial.Efficacy assessment based on symptom score reducing index(SSRI)showed that the effective rate of mizolastine and loratadine were80.8%and74.5%respectively,no statistically significant difference was observed28days after treatment between two groups(χ2 =1.16,P=0.28).The scores of the diameter of largest wheal,weekly urticaria episodes and VAS score in mizolastine group were decreased significantly than those in loratadine group7days after treatment(P=0.05,P=0.03and P=0.02).But there was no statistically significant different between two groups14and28days after treatment(P0.05).No serious adverse events were reported in these two groups.The incidences of adverse event of mizolastine and loratadine were28.6%and25.5%respectively,there were no statistically significant difference between two groups(χ 2 =0.25,P=0.62).Conclusions The efficacy of mizolastine and loratadine is similar in the treatment of CIU,but mizolastine is quicker in action than loratadine.The incidences of adverse events are not different in the two groups." @default.
- W2377771057 created "2016-06-24" @default.
- W2377771057 creator A5001647048 @default.
- W2377771057 creator A5007630798 @default.
- W2377771057 creator A5025832492 @default.
- W2377771057 creator A5027185198 @default.
- W2377771057 creator A5052344563 @default.
- W2377771057 creator A5063976858 @default.
- W2377771057 creator A5081352901 @default.
- W2377771057 date "2003-06-15" @default.
- W2377771057 modified "2023-10-15" @default.
- W2377771057 title "A Multicentre,Double-blind,Randomized,Parallel Comparative Study on the Efficacy and Safety of Mizolastine versus Loratadine in the Treatment of Chronic Urticaria" @default.
- W2377771057 hasPublicationYear "2003" @default.
- W2377771057 type Work @default.
- W2377771057 sameAs 2377771057 @default.
- W2377771057 citedByCount "0" @default.
- W2377771057 crossrefType "journal-article" @default.
- W2377771057 hasAuthorship W2377771057A5001647048 @default.
- W2377771057 hasAuthorship W2377771057A5007630798 @default.
- W2377771057 hasAuthorship W2377771057A5025832492 @default.
- W2377771057 hasAuthorship W2377771057A5027185198 @default.
- W2377771057 hasAuthorship W2377771057A5052344563 @default.
- W2377771057 hasAuthorship W2377771057A5063976858 @default.
- W2377771057 hasAuthorship W2377771057A5081352901 @default.
- W2377771057 hasConcept C126322002 @default.
- W2377771057 hasConcept C141071460 @default.
- W2377771057 hasConcept C14184104 @default.
- W2377771057 hasConcept C168563851 @default.
- W2377771057 hasConcept C197934379 @default.
- W2377771057 hasConcept C2779923671 @default.
- W2377771057 hasConcept C2780734495 @default.
- W2377771057 hasConcept C3017745231 @default.
- W2377771057 hasConcept C42219234 @default.
- W2377771057 hasConcept C71924100 @default.
- W2377771057 hasConcept C90924648 @default.
- W2377771057 hasConceptScore W2377771057C126322002 @default.
- W2377771057 hasConceptScore W2377771057C141071460 @default.
- W2377771057 hasConceptScore W2377771057C14184104 @default.
- W2377771057 hasConceptScore W2377771057C168563851 @default.
- W2377771057 hasConceptScore W2377771057C197934379 @default.
- W2377771057 hasConceptScore W2377771057C2779923671 @default.
- W2377771057 hasConceptScore W2377771057C2780734495 @default.
- W2377771057 hasConceptScore W2377771057C3017745231 @default.
- W2377771057 hasConceptScore W2377771057C42219234 @default.
- W2377771057 hasConceptScore W2377771057C71924100 @default.
- W2377771057 hasConceptScore W2377771057C90924648 @default.
- W2377771057 hasIssue "6" @default.
- W2377771057 hasLocation W23777710571 @default.
- W2377771057 hasOpenAccess W2377771057 @default.
- W2377771057 hasPrimaryLocation W23777710571 @default.
- W2377771057 hasRelatedWork W1481582318 @default.
- W2377771057 hasRelatedWork W1508479020 @default.
- W2377771057 hasRelatedWork W1973371587 @default.
- W2377771057 hasRelatedWork W2013137237 @default.
- W2377771057 hasRelatedWork W2023748393 @default.
- W2377771057 hasRelatedWork W2024931777 @default.
- W2377771057 hasRelatedWork W2037803669 @default.
- W2377771057 hasRelatedWork W2075333179 @default.
- W2377771057 hasRelatedWork W2188585965 @default.
- W2377771057 hasRelatedWork W2356357361 @default.
- W2377771057 hasRelatedWork W2356793954 @default.
- W2377771057 hasRelatedWork W2373704842 @default.
- W2377771057 hasRelatedWork W2373835182 @default.
- W2377771057 hasRelatedWork W2376832034 @default.
- W2377771057 hasRelatedWork W2378317616 @default.
- W2377771057 hasRelatedWork W2386273670 @default.
- W2377771057 hasRelatedWork W2390751556 @default.
- W2377771057 hasRelatedWork W2402358832 @default.
- W2377771057 hasRelatedWork W5548006 @default.
- W2377771057 hasRelatedWork W3046241280 @default.
- W2377771057 hasVolume "36" @default.
- W2377771057 isParatext "false" @default.
- W2377771057 isRetracted "false" @default.
- W2377771057 magId "2377771057" @default.
- W2377771057 workType "article" @default.